Abstract: A method for operating a motor vehicle configured as an electric or hybrid vehicle during its charging process, including: generating a charging signal by the motor vehicle, such that the charging signal indicates an imminent charging of the motor vehicle taking place at a charging station; detecting the charging signal by a control device; detecting at least one presence information item once the charging signal has been detected by way of at least one sensor of the motor vehicle, such that the presence information item relates to the presence or absence of at least one stranger located in a vicinity of the motor vehicle; checking for the fulfillment of an action condition by way of the control device, such that the action condition is fulfilled if the presence information item verifies that a stranger is present; generating and outputting at least one control signal by the control device.

Abstract: An energy storage device for a motor vehicle includes a battery module and at least one thermally insulating filling element, which is preferably designed as a thermally insulating cell separator element arranged between two battery cells of the battery module. The filling element is designed to be soluble here, so that it dissolves at least in part when it comes into contact with a specific minimum amount of a specific liquid.

Abstract: A cosmetic method for modulating pigmentation in a subject includes administering a modulator of angiotensin-converting enzyme 2 (ACE2 modulator) to the subject. The ACE2 modulator can be an inhibitor of angiotensin-converting enzyme 2 (ACE2 inhibitor), in which case, the ACE2 inhibitor can be administered to increase pigmentation in the subject. The ACE2 modulator can also be an activator of angiotensin-converting enzyme 2 (ACE2 activator), in which case the ACE2 activator can be administered to decrease pigmentation in the subject. The treatment of inflammatory skin disease can also be achieved by inhibition of angiotensin-converting enzyme 2.

Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.

Abstract: A cosmetic method for modulating pigmentation in a subject includes administering a modulator of angiotensin-converting enzyme 2 (ACE2 modulator) to the subject. The ACE2 modulator can be an inhibitor of angiotensin-converting enzyme 2 (ACE2 inhibitor), in which case, the ACE2 inhibitor can be administered to increase pigmentation in the subject. The ACE2 modulator can also be an activator of angiotensin-converting enzyme 2 (ACE2 activator), in which case the ACE2 activator can be administered to decrease pigmentation in the subject. The treatment of inflammatory skin disease can also be achieved by inhibition of angiotensin-converting enzyme 2.

Abstract: A support bracket may include a base portion having an upper surface and a lower surface for resting on a surface, and a mount portion securely mounted on the base portion. The mount portion may include a perimeter wall having a lower end mounted on the base portion such that the mount portion extends away from the upper surface, and an upper end with an upper opening. The bracket may form a socket for receiving a lower end portion of an upright post. The socket may have a cross section size with a width and a depth, and a length substantially equal to the maximum extent to which the lower end portion of the upright post is insertable into the socket. The length of the socket may be greater than approximately two times the width of the socket.

Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.

Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.

Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.

Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.

Abstract: A manufacturing process of a hot stamped coated part comprising the following successive steps, in this order: providing a hot rolled or cold rolled steel sheet comprising a steel substrate and an aluminium-silicon alloy precoating, the precoating containing more than 50% of free aluminium and having a thickness comprised between 15 and 50 micrometers, then cutting the steel sheet to obtain a precoated steel blank, then heating the blank under non protective atmosphere up to a temperature Ti comprised between Te?10° C. and Te, Te being the eutectic or solidus temperature of the precoating, then heating the blank from the temperature Ti up to a temperature Tm comprised between 840 and 950° C. under non protective atmosphere with a heating rate V comprised between 30° C./s and 90° C.

Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.

Abstract: A stabilized high-voltage power supply is disclosed, having a general setup similar to a pulse-step modulator. The power supply comprises a plurality of DC power modules (40) having their outputs connected in a series configuration. Each power module comprises a DC voltage source (41), a DC-DC converter (42), and an output switching circuit (43). The total output voltage of the power supply is regulated by regulating the DC link voltage at the output of each power module. This is achieved by an appropriate feedback control circuit driving the DC-DC converter of each power module. In this manlier, low output ripple and a rapid response to changes in output current can be achieved. The power supply may be used, e.g., as the cathode power supply of a gyrotron.

Abstract: A stabilized high-voltage power supply is disclosed, having a general setup similar to a pulse-step modulator. The power supply comprises a plurality of DC power modules (40) having their outputs connected in a series configuration. Each power module comprises a DC voltage source (41), a DC-DC converter (42), and an output switching circuit (43). The total output voltage of the power supply is regulated by regulating the DC link voltage at the output of each power module. This is achieved by an appropriate feedback control circuit driving the DC-DC converter of each power module. In this manlier, low output ripple and a rapid response to changes in output current can be achieved. The power supply may be used, e.g., as the cathode power supply of a gyrotron.

Abstract: The present invention relates to the gene Gpnmb and its use as a genetic marker in the incidence of cardiovascular conditions and cardiac diseases, such as complications derived from myocardial infarction. Gpnmb provides a valuable tool both for diagnostic as well as therapeutic approaches, in order to treat or prevent cardiovascular conditions and cardiac diseases, in particular complications derived from myocardial infarction.

Abstract: The present invention is characterized by the use of Mas-G-protein-coupled receptor agonists for the control, prevention and treatment of the body levels of triglycerides, cholesterol and glucose, as well as of hyper-tension and possible increase in body weight, which are characteristic of the clinical manifestation of the metabolic syndrome and its complications. Another characteristic of the invention is the use of Mas-G-protein-coupled receptor agonists, including the Angiotensin-(1-7) peptide and its analogs, agonists, either peptidic or non-peptidic, as modulators of the manifestations of insulin resistance and glucose intolerance and in the prevention and treatment of the related alterations.

Abstract: A manufacturing process of a hot stamped coated part comprising the following successive steps, in this order: providing a hot rolled or cold rolled steel sheet comprising a steel substrate and an aluminium-silicon alloy precoating, the precoating containing more than 50% of free aluminium and having a thickness comprised between 15 and 50 micrometers, then cutting the steel sheet to obtain a precoated steel blank, then heating the blank under non protective atmosphere up to a temperature Ti comprised between Te?10° C. and Te, Te being the eutectic or solidus temperature of the precoating, then heating the blank from the temperature Ti up to a temperature Tm comprised between 840 and 950° C. under non protective atmosphere with a heating rate V comprised between 30° C./s and 90° C.

Abstract: The present invention is characterized by the use of Mas-G-protein-coupled receptor agonists for the control, prevention and treatment of the body levels of triglycerides, cholesterol and glucose, as well as of hyper-tension and possible increase in body weight, which are characteristic of the clinical manifestation of the metabolic syndrome and its complications. Another characteristic of the invention is the use of Mas-G-protein-coupled receptor agonists, including the Angiotensin-(1-7) peptide and its analogs, agonists, either peptidic or non-peptidic, as modulators of the manifestations of insulin resistance and glucose intolerance and in the prevention and treatment of the related alterations.

Abstract: The present invention relates to a biological entity, notably a rat, carrying a regulator construct comprising a specific repressor gene and a responder construct comprising at least one segment corresponding to a short hairpin RNA (shRNA) or corresponding to complementary short interfering RNA (siRNA) strands or corresponding to miRNA, said at least one segment being under control of a promoter which contains an operator sequence corresponding to the repressor. The invention further relates to a method for preparing said biological entity and its use.

Abstract: The invention provides novel compositions, methods and uses, for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia and breast cancer. The invention further relates to genes that are differentially expressed in breast tissue of breast cancer patients versus those of normal “healthy” tissue. Differentially expressed genes for the identification of patients which are likely to respond to chemotherapy are also provided.